Analytical Data
-
基因名
CD52
-
简介
The CD52 protein may play a role in the carriage and targeting of carbohydrates, suggesting its involvement in cellular processes related to carbohydrate transport. Additionally, CD52 may have a more specific role that requires further investigation. CD52 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD52 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of CD52 Protein, Human (Biotinylated, HEK293, His-Avi) is 12 a.a., with molecular weight of ~16 kDa.
- Application
-
别名
CDW52; HE5; CD52; CAMPATH-1 antigen
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P31358
-
表达区间
G25-S36
-
分子量
16 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD52 is a glycoprotein expressed on the surface of certain immune cells, playing a crucial role in immune regulation. Research on CD52 has gained significant traction due to its implications in various diseases, particularly in hematological malignancies and autoimmune disorders. The protein is the target of the monoclonal antibody alemtuzumab, which has been utilized in the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS). By depleting CD52-expressing T and B lymphocytes, alemtuzumab effectively modulates the immune response, offering therapeutic benefits. However, the development of CD52-targeting therapies raises questions about potential side effects, such as increased susceptibility to infections and the risk of secondary malignancies. As a result, understanding the structure, function, and signaling pathways associated with CD52 is critical for optimizing existing treatments and developing new immunotherapeutic strategies. Recent advances in recombinant protein technology have enabled the production of CD52 fusion proteins, which can be used to investigate its biological functions and interactions. Additionally, these recombinant forms can serve as valuable tools for diagnostic and therapeutic applications, enhancing our capacity to manipulate the immune system. Through ongoing research, CD52 remains a promising candidate for novel treatment modalities aimed at improving patient outcomes in a range of immunological conditions.
